{"slug":"ghk-cu","verification":{"valid":true,"entries":42,"head":"80e83bfe2acf6a33f805fa7afff5e651657ee929b170f54d771c9f30ee457cc4"},"energy":{"passes":42,"tokens_in":3287,"tokens_out":429,"tokens_total":3716,"cost_usd":0,"models":{"grok/grok-4.3":1,"grok-4.3":23,"repair":2,"system/audit-repair":11,"kimi/moonshot-v1-8k":1,"fill-slots":3,"owner":1},"head":"80e83bfe2acf6a33f805fa7afff5e651657ee929b170f54d771c9f30ee457cc4"},"provenance":[{"ts":"2026-06-29T08:34:09.954Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"PEPTIDE DEFINITIONS (use for mechanism accuracy; no medical claims):\nBPC-157 — Body Protection Compound. Derived from gastric juice protein. Builds new blood vessels into damaged tissue locally. 100+ animal/cell studies (tendon, gut, muscle, bone, nerve).\nTB-500 — Synthetic Thymosin Beta-4. Moves repair cells to damage; clears stuck inflammation systemically. Production drops ~60% by age 60.\nARA-290 — Nerve repair peptide with human clinical trial data. Regrows damaged nerves; does not mask nerve pain.\nSemax — Brain peptide; upregulates BDNF for neuroprotection and cognitive recovery.\nSelank — Anxiolytic peptide; reduces anxiety without sedation or addiction (non-benzodiazepine pathway).\nPT-141 — Sexual function; brain-level arousal signaling (FDA-approved mechanism as Vyleesi).\nDSIP — Delta Sleep Inducing Peptide; natural deep sleep without Ambien-class hangover.\nKPV — Gut-specific anti-inflammatory; calms gut lining without systemic immune suppression.\nGHK-Cu — Tissue remodeling; builds collagen scaffolding. Production drops 60-80% with age.\nThymosin Alpha-1 — Immune modulation; supports immune function without suppressing it.\n\nWrite a data-first, evidence-graded article: GHK-Cu: Collagen Scaffolding\n\nGeneral evidence-graded intro for GHK-Cu: Collagen Scaffolding. Data-first peptide definition article.\n\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate rat studies from human trials from user reports. No medical claims or treatment promises. Use repair-vs-suppression framing where relevant. register: source_ledger.","response":"{\n  \"slug\": \"ghk-cu-collagen-scaffolding\",\n  \"title\": \"GHK-Cu: Collagen Scaffolding\",\n  \"body\": \"## GHK-Cu: Collagen Scaffolding\\n\\nGHK-Cu (glycyl-L-histidyl-L-lysine copper) is a naturally occurring copper-binding tripeptide first isolated from human plasma.\\n\\n### Plasma Levels and Age-Related Decline\\nPlasma GHK levels measure approximately 200 ng/mL at age 20 and decline to approximately 80 ng/mL by age 60 (human plasma measurements).\\n\\n### Collagen and Extracellular Matrix Effects\\nIn human dermal fibroblast cultures, GHK-Cu at nanomolar concentrations increases synthesis of collagen types I, III, and IV as well as elastin and glycosaminoglycans (preclinical, human cell studies). It also modulates matrix metalloproteinases and their inhibitors, supporting both synthesis and organized remodeling of collagen (mechanistic).\\n\\nPlacebo-controlled topical application studies in women around age 50 reported improved skin quality parameters and increased collagen deposition in skin biopsies (human).\\n\\nNo large-scale systemic human trials on collagen scaffolding outcomes are available.\\n\\n### Wound Healing and Tissue Remodeling Context\\nA registered Phase 2 randomized double-blind trial (NCT07437586) is evaluating topical GHK-Cu gel versus vehicle for acute skin wound re-epithelialization in healthy adults (human trial, ongoing/registered).\\n\\nGene-expression studies in human cells link GHK-Cu exposure to patterns associated with improved fibroblast function and collagen reorganization (mechanistic).\\n\\n### Summary of Evidence Tiers\\n- Age-related decline in circulating GHK: human data.\\n- Stimulation of collagen production: primarily preclinical (human fibroblasts in vitro) with limited supporting human topical biopsy data.\\n- Systemic tissue remodeling claims: no human data.\",\n  \"register\": \"source_ledger\",\n  \"claims\": [\n    {\n      \"id\": \"c1\",\n      \"text\": \"Plasma GHK levels measure approximately 200 ng/mL at age 20 and decline to approximately 80 ng/mL by age 60","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"13332b25ec730fa88d7ac2076f517078d3cc8cc4c4dda4e9acf5ac07ea285d55"},{"ts":"2026-06-29T09:57:04.703Z","model":"grok-4.3","action":"sources","prompt":"","input":"ghk-cu","response":"7 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"13332b25ec730fa88d7ac2076f517078d3cc8cc4c4dda4e9acf5ac07ea285d55","hash":"0ddf839ebfd0da0a26d831fe76c535a768220e6b2e3cd3b7b34a3065c8346460"},{"ts":"2026-06-29T09:57:33.707Z","model":"grok-4.3","action":"sources","prompt":"","input":"ghk-cu","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"0ddf839ebfd0da0a26d831fe76c535a768220e6b2e3cd3b7b34a3065c8346460","hash":"2af33fd3c041d9e4710e28f06096044160a78ace02a0885ccd69d62bad85597f"},{"ts":"2026-06-29T09:57:54.133Z","model":"grok-4.3","action":"sources","prompt":"","input":"ghk-cu","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"2af33fd3c041d9e4710e28f06096044160a78ace02a0885ccd69d62bad85597f","hash":"e7de92327dc84fd14346ef3b370f78086e488eb67cebbdb9f818531696325625"},{"ts":"2026-06-29T09:58:13.646Z","model":"grok-4.3","action":"sources","prompt":"","input":"ghk-cu","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"e7de92327dc84fd14346ef3b370f78086e488eb67cebbdb9f818531696325625","hash":"dea4dd0690b2659c3be7d26c5c476323b5e01127a43271f9461505ea14d24d12"},{"ts":"2026-06-29T09:59:13.165Z","model":"grok-4.3","action":"sources","prompt":"","input":"ghk-cu","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"dea4dd0690b2659c3be7d26c5c476323b5e01127a43271f9461505ea14d24d12","hash":"c823da6fe3ca18908af19eeffe0efe5b5843cfaf0fb05678948b2913e12d0b62"},{"ts":"2026-06-29T09:59:36.302Z","model":"grok-4.3","action":"sources","prompt":"","input":"ghk-cu","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"c823da6fe3ca18908af19eeffe0efe5b5843cfaf0fb05678948b2913e12d0b62","hash":"fd8c689f36855dc605b68dfe2930ac5d86d3a05895c30f72b4bf57b8b06bc804"},{"ts":"2026-06-29T09:59:51.703Z","model":"grok-4.3","action":"sources","prompt":"","input":"ghk-cu","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"fd8c689f36855dc605b68dfe2930ac5d86d3a05895c30f72b4bf57b8b06bc804","hash":"2bb36c04c58875c9295a23f348e71b6ba819a045dacad1869f257170a250b339"},{"ts":"2026-06-29T10:00:17.825Z","model":"grok-4.3","action":"sources","prompt":"","input":"ghk-cu","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"2bb36c04c58875c9295a23f348e71b6ba819a045dacad1869f257170a250b339","hash":"40604f1d9087b50a6083a8b294cf0b2022ff7fef3a8e569a24959eaa352d5d82"},{"ts":"2026-06-29T10:01:20.741Z","model":"grok-4.3","action":"sources","prompt":"","input":"ghk-cu","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"40604f1d9087b50a6083a8b294cf0b2022ff7fef3a8e569a24959eaa352d5d82","hash":"d40eadb8ff57cdc326ae29a1cfeb18919bff925c7eaa9d9f5a8ad50055ecca05"},{"ts":"2026-06-29T10:01:45.831Z","model":"grok-4.3","action":"sources","prompt":"","input":"ghk-cu","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"d40eadb8ff57cdc326ae29a1cfeb18919bff925c7eaa9d9f5a8ad50055ecca05","hash":"c3d88de1b288fd9cde9453cdf4b7814f0722cd987d98216406d20e1f1a526dfd"},{"ts":"2026-06-29T10:02:09.219Z","model":"grok-4.3","action":"sources","prompt":"","input":"ghk-cu","response":"8 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"c3d88de1b288fd9cde9453cdf4b7814f0722cd987d98216406d20e1f1a526dfd","hash":"d17e6565f24ac304a40a0062c02807506683658ecc102c30810a2b879dd4b846"},{"ts":"2026-06-29T10:03:14.001Z","model":"grok-4.3","action":"sources","prompt":"","input":"ghk-cu","response":"7 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"d17e6565f24ac304a40a0062c02807506683658ecc102c30810a2b879dd4b846","hash":"867a2daee2593f9406b93ea786b7f496a9f802a35bf1a9c095c9b692ea68c306"},{"ts":"2026-06-29T10:03:35.113Z","model":"grok-4.3","action":"sources","prompt":"","input":"ghk-cu","response":"10 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"867a2daee2593f9406b93ea786b7f496a9f802a35bf1a9c095c9b692ea68c306","hash":"331966fb097ab0421bf21e4302d477e0aee7f9835a361daebb1a63ef88d904bf"},{"ts":"2026-06-29T10:03:54.427Z","model":"grok-4.3","action":"sources","prompt":"","input":"ghk-cu","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"331966fb097ab0421bf21e4302d477e0aee7f9835a361daebb1a63ef88d904bf","hash":"5b60ce385248471790c70e306edd469c170c243c7cf1992b6b8b223b4d717824"},{"ts":"2026-06-29T10:04:17.982Z","model":"grok-4.3","action":"sources","prompt":"","input":"ghk-cu","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"5b60ce385248471790c70e306edd469c170c243c7cf1992b6b8b223b4d717824","hash":"1e39f9487bcffe4a3cd94e46e0113f065ea87e95a4675076c568a40c46e6ede2"},{"ts":"2026-06-29T10:05:12.925Z","model":"grok-4.3","action":"sources","prompt":"","input":"ghk-cu","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"1e39f9487bcffe4a3cd94e46e0113f065ea87e95a4675076c568a40c46e6ede2","hash":"4e7081cba8abc3065aae817ce79f24656de5ce1f0295674f32ee5aa234b92e5f"},{"ts":"2026-06-29T10:05:37.285Z","model":"grok-4.3","action":"sources","prompt":"","input":"ghk-cu","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"4e7081cba8abc3065aae817ce79f24656de5ce1f0295674f32ee5aa234b92e5f","hash":"6da8a3bdefa0a75b9970b5ed4e22672a3772c4b1e6293666887e4d03997398e5"},{"ts":"2026-06-29T12:29:45.112Z","model":"repair","action":"repair","prompt":"","input":"ghk-cu","response":"{\"materialized\":89,\"before\":[\"4 claims missing posted_by\",\"89 orphan sources (no claim link)\",\"missing constitution slots: what_it_is, who_claims_what, what_is_known, what_is_unknown, limitations, disclaimer\"],\"after\":[\"missing constitution slots: what_it_is, what_is_known, what_is_unknown, limitations, disclaimer\"]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"6da8a3bdefa0a75b9970b5ed4e22672a3772c4b1e6293666887e4d03997398e5","hash":"82be127eef1c24f4aa28c6bf06db9433dd03c5f77bcb363fa4a269ca393c5880"},{"ts":"2026-06-29T12:46:21.329Z","model":"system/audit-repair","action":"repair","prompt":"","input":"ghk-cu","response":"{\"materialized\":0,\"before\":[\"missing constitution slots: what_it_is, what_is_known, what_is_unknown, limitations, disclaimer\"],\"after\":[\"missing constitution slots: what_it_is, what_is_known, what_is_unknown, limitations, disclaimer\"]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"82be127eef1c24f4aa28c6bf06db9433dd03c5f77bcb363fa4a269ca393c5880","hash":"9425c6c812d4696d934c4912155010cee8c458f44ccb3244fea144a1d286c45d"},{"ts":"2026-06-29T12:46:22.013Z","model":"system/audit-repair","action":"claim","prompt":"","input":"ghk-cu c94","response":"GHK-Cu: Collagen Scaffolding is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9425c6c812d4696d934c4912155010cee8c458f44ccb3244fea144a1d286c45d","hash":"b5b812d093b146c00506df16a4ba92cc097b1f60e07ee42b5288fd03a6880532"},{"ts":"2026-06-29T12:46:22.108Z","model":"system/audit-repair","action":"claim","prompt":"","input":"ghk-cu c95","response":"Per this ledger on GHK-Cu: Collagen Scaffolding: 42 scientific and 48 anecdotal sources are catalogued; 25 preclinical claim(s) summarize animal/cell literature in-catalogue.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"b5b812d093b146c00506df16a4ba92cc097b1f60e07ee42b5288fd03a6880532","hash":"999b986ef4cd98e53f75578bf202bc346e76ae3886e08e0f4559436273908a74"},{"ts":"2026-06-29T12:46:22.220Z","model":"system/audit-repair","action":"claim","prompt":"","input":"ghk-cu c96","response":"Not established in this ledger: large randomized human trials for common marketed uses; long-term human safety beyond small pilots; condition-specific efficacy where only anecdotal or preclinical sources exist (explicit gaps remain in question graph).","tokens_in":0,"tokens_out":0,"cost":0,"prev":"999b986ef4cd98e53f75578bf202bc346e76ae3886e08e0f4559436273908a74","hash":"ba2adb2d7610481be46554b2c0579c0f03c0e9d4715b9e12f2283db6c61dd7d9"},{"ts":"2026-06-29T12:46:22.530Z","model":"system/audit-repair","action":"claim","prompt":"","input":"ghk-cu c97","response":"Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"ba2adb2d7610481be46554b2c0579c0f03c0e9d4715b9e12f2283db6c61dd7d9","hash":"f9fa3fbed71545123930ddebc836c5bfb9b797f5b980c6497681e24d744ec598"},{"ts":"2026-06-29T12:46:22.647Z","model":"system/audit-repair","action":"claim","prompt":"","input":"ghk-cu c98","response":"Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"f9fa3fbed71545123930ddebc836c5bfb9b797f5b980c6497681e24d744ec598","hash":"9bbc2c1b80ccf9f68002746a87bc363e2a5421bbe480c9673e502163a4288455"},{"ts":"2026-06-29T12:46:23.767Z","model":"system/audit-repair","action":"repair","prompt":"","input":"ghk-cu","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9bbc2c1b80ccf9f68002746a87bc363e2a5421bbe480c9673e502163a4288455","hash":"b020a291a2b4f3f9fb9301f4255add2fd6ff1a2a02ea3dfc295e1ccaf7139da3"},{"ts":"2026-06-29T13:25:23.884Z","model":"system/audit-repair","action":"repair","prompt":"","input":"ghk-cu","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"b020a291a2b4f3f9fb9301f4255add2fd6ff1a2a02ea3dfc295e1ccaf7139da3","hash":"e975dc94dcf6305d613531e65305da73ddbfb28ba820b91ac27b08924687839b"},{"ts":"2026-06-29T13:25:25.024Z","model":"system/audit-repair","action":"repair","prompt":"","input":"ghk-cu","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"e975dc94dcf6305d613531e65305da73ddbfb28ba820b91ac27b08924687839b","hash":"0e777a7ec246da5b62b9d595e6598fdf2efe46805255b09b3852c3da13576937"},{"ts":"2026-06-29T13:46:48.242Z","model":"kimi/moonshot-v1-8k","action":"collaborate","prompt":"","input":"ghk-cu","response":"I am adding explicit gaps regarding what is unknown and naming who claims what from anecdotes as instructed. I am not Grok because I am following the instructions to add specific types of claims and not inventing any URLs or providing medical advice.","tokens_in":3287,"tokens_out":429,"cost":0,"prev":"0e777a7ec246da5b62b9d595e6598fdf2efe46805255b09b3852c3da13576937","hash":"5c36ddc23b068bbec5cd89264cebe8248715c70a236fbfd02e561f71b216dc4c"},{"ts":"2026-06-29T13:53:54.193Z","model":"system/audit-repair","action":"repair","prompt":"","input":"ghk-cu","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"5c36ddc23b068bbec5cd89264cebe8248715c70a236fbfd02e561f71b216dc4c","hash":"8cce909d622a370a96c4896c1d3f3a6b06361c8148e85921b1432b8eca16ce1b"},{"ts":"2026-06-29T13:53:55.408Z","model":"system/audit-repair","action":"repair","prompt":"","input":"ghk-cu","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"8cce909d622a370a96c4896c1d3f3a6b06361c8148e85921b1432b8eca16ce1b","hash":"361a67260505a0db3518a5b81f28a53febdc40bd9ba4a6fce940548f763dfc07"},{"ts":"2026-06-29T15:38:26.903Z","model":"grok-4.3","action":"sources","prompt":"","input":"ghk-cu","response":"2 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"361a67260505a0db3518a5b81f28a53febdc40bd9ba4a6fce940548f763dfc07","hash":"2875fc5acc375227c4031b47a29fb0083dc54eea1c047420d23c37c90578b3b2"},{"ts":"2026-06-29T15:38:52.327Z","model":"grok-4.3","action":"sources","prompt":"","input":"ghk-cu","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"2875fc5acc375227c4031b47a29fb0083dc54eea1c047420d23c37c90578b3b2","hash":"aad578305aebe491562a5d81d1c5db53a57e8112c54f5b986bdcee82cbea3cb1"},{"ts":"2026-06-29T15:39:12.179Z","model":"grok-4.3","action":"sources","prompt":"","input":"ghk-cu","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"aad578305aebe491562a5d81d1c5db53a57e8112c54f5b986bdcee82cbea3cb1","hash":"f53b3e03492a76ba248a1993abb8d5bde28ca9d3b0ef39fcf72518bf93c44fd4"},{"ts":"2026-06-29T15:39:41.680Z","model":"grok-4.3","action":"sources","prompt":"","input":"ghk-cu","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"f53b3e03492a76ba248a1993abb8d5bde28ca9d3b0ef39fcf72518bf93c44fd4","hash":"0847bc9b6f434caeaf92280319691f281e048e64da9f7eb6ce3f2050eee2f1ea"},{"ts":"2026-06-29T15:40:32.585Z","model":"grok-4.3","action":"sources","prompt":"","input":"ghk-cu","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"0847bc9b6f434caeaf92280319691f281e048e64da9f7eb6ce3f2050eee2f1ea","hash":"13a7f75d9f253c0c9f3837e8edaa133e96840a8b4d9ee8d005fa5dee35d804d6"},{"ts":"2026-06-29T17:41:29.329Z","model":"grok-4.3","action":"sources","prompt":"","input":"ghk-cu","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"13a7f75d9f253c0c9f3837e8edaa133e96840a8b4d9ee8d005fa5dee35d804d6","hash":"f09374ae00afa88709039ad299ead13c55f4f79a2cf7690a09cabb2681f225ab"},{"ts":"2026-06-29T19:29:03.796Z","model":"repair","action":"repair","prompt":"","input":"ghk-cu","response":"{\"materialized\":0,\"before\":[],\"after\":[],\"focus_stats\":{\"roles_assigned\":0,\"excluded_sources\":0,\"commercial_sources\":0,\"cut_claims\":0,\"core\":0,\"cycle\":0,\"adjacent\":18}}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"f09374ae00afa88709039ad299ead13c55f4f79a2cf7690a09cabb2681f225ab","hash":"ef34ac07445abdb38075fcce0c3fb6cb11175572f85a9f8617034f4fd48752b9"},{"ts":"2026-06-29T20:43:02.350Z","model":"fill-slots","action":"claim","prompt":"","input":"ghk-cu c116","response":"GHK-Cu: Collagen Scaffolding is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"ef34ac07445abdb38075fcce0c3fb6cb11175572f85a9f8617034f4fd48752b9","hash":"c6b406a2abecaba5683be26f9fdb5133e63cece0adb1b9f8808eb202deb0b308"},{"ts":"2026-06-29T20:43:05.333Z","model":"fill-slots","action":"claim","prompt":"","input":"ghk-cu c117","response":"Not established in this ledger: large randomized human trials for common marketed uses; long-term human safety beyond small pilots; condition-specific efficacy where only anecdotal or preclinical sources exist (explicit gaps remain in question graph).","tokens_in":0,"tokens_out":0,"cost":0,"prev":"c6b406a2abecaba5683be26f9fdb5133e63cece0adb1b9f8808eb202deb0b308","hash":"51e0abbe61068818673f5c87b97c4970028b4db4873e764c940a98090f02a2d4"},{"ts":"2026-06-29T20:43:07.000Z","model":"fill-slots","action":"claim","prompt":"","input":"ghk-cu c118","response":"Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"51e0abbe61068818673f5c87b97c4970028b4db4873e764c940a98090f02a2d4","hash":"f8a1c4069d2b1909e78f6b5a273f270311d61d7054f3c50582d32216ecfc094a"},{"ts":"2026-07-17T02:39:18.681Z","model":"owner","action":"voxel_divide","prompt":"","input":"ghk-cu","response":"13 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"f8a1c4069d2b1909e78f6b5a273f270311d61d7054f3c50582d32216ecfc094a","hash":"80e83bfe2acf6a33f805fa7afff5e651657ee929b170f54d771c9f30ee457cc4"}]}